Tirzepatide compound claims on TikTok: what the data says

What did @lovesavedtheday actually say?

This is a promotional unboxing video for a telehealth platform called JoinFridays. The creator says she has been on GLP-1 medication through them since October, claims she is "down 47 pounds," and offers a discount code for $100 off a first month of compounded tirzepatide or semaglutide. She describes the package contents, including ice packs, syringes, alcohol pads, and a vial of medication, and notes she stepped back down to 7.5 mg tirzepatide from 10 mg.

She also lists services the platform offers: "one-on-one coaching, nutrition coaching, movement coaching" and "unlimited access to providers." The video closes with a direct call to action using her affiliate code T100. To be clear, this is an advertisement, whether or not it is labeled as one.

Does the science back this up?

The weight loss claim is plausible. The coaching claims are reasonable in concept, though the evidence for telehealth-delivered GLP-1 programs specifically is still developing.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at doses between 5 mg and 15 mg produced mean weight reductions of 15 to 20.9 percent of body weight over 72 weeks. A 47-pound loss is consistent with that range depending on starting weight. Reducing from 10 mg back to 7.5 mg is a real thing patients do to manage side effects or because they were already responding well at a lower dose, and clinical practice supports that approach.

On coaching: a 2023 study by Tronieri et al. in Obesity found that behavioral support alongside GLP-1 therapy improved adherence and outcomes compared to medication alone. So the platform offering nutrition and movement coaching is not just marketing fluff. Whether the coaching JoinFridays provides meets any clinical standard is something this video cannot tell you.

What did they get wrong (or right)?

A few things to flag here. First, the video promotes compounded tirzepatide, which is not the same as FDA-approved Zepbound or Mounjaro. The creator never makes that distinction. Compounded tirzepatide is produced by 503A or 503B pharmacies and is not FDA-approved. Potency, sterility, and dosing consistency vary. That is not a minor footnote.

Second, saying the discount code offer is available "for this month only" is a pressure tactic, not medical guidance. Third, the creator says she self-adjusted her dose, noting she "was on 10, but I don't want to exceed" and returned to 7.5 mg. Whether that was provider-directed or self-directed is unclear. If it was self-directed, that is worth flagging. Dose adjustments should happen with clinical oversight, not personal preference alone.

What she got right: the general package contents she describes, including cold storage, syringes, alcohol pads, and injection site guidance, reflect standard compounding pharmacy fulfillment practices. That part is accurate.

What should you actually know?

If you are considering a telehealth GLP-1 program, a few things matter more than an unboxing video. First, verify that any platform you use employs licensed prescribers who conduct a real clinical intake, not just a checkbox form. Second, compounded tirzepatide is in a regulatory gray area. The FDA removed tirzepatide from its drug shortage list in 2024, which means compounding pharmacies may no longer legally produce copies of it under 503A rules. Check the current status before purchasing.

Third, 47 pounds lost is a meaningful result, and GLP-1 medications do produce significant weight loss for many people. But individual results vary widely. The SURMOUNT-1 trial showed a range, not a guarantee. A telehealth platform's coaching quality also ranges widely. Ask specific questions about who provides the coaching and what their credentials are before signing up based on an affiliate code.